nyuuzyou/wikis huggingface dataset:
Thioguanine (Tabloid)

==General information==
Class/mechanism: Purine (guanine) analog, antimetabolite that interferes with DNA synthesis. Thioguanine competes with hypoxanthine and guanine for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) and is converted to 6-thioguanylic acid (TGMP). TGMP interferes with several processes involving the synthesis of guanine nucleotides. It exerts pseudo-feedback inhibition of glutamine-5-phosphoribosylpyrophosphate amidotransferase, an early enzyme in the de novo pathway for purine ribonucleotide synthesis. TGMP is a competitive inhibitor of inosinic acid (IMP) dehydrogenase, interfering with the conversion of IMP to xanthylic acid (XMP). Thioguanylic acid is converted to thioguanosine diphosphate (TGDP) and thioguanosine triphosphate (TGTP), and they are eventually incorporated into RNA and DNA, which may cause additional cytotoxicity. Thioguanine is structurally and functionally similar to Mercaptopurine (6-MP).Thioguanine (Tabloid) package insertThioguanine (Tabloid) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. 
==Diseases for which it is used==
*Acute promyelocytic leukemia
*B-cell acute lymphoblastic leukemia
*Waldenström macroglobulinemia
==Diseases for which it was used==
*Acute myeloid leukemia
==Patient drug information==
*Thioguanine (Tabloid) patient drug information (Chemocare)Thioguanine (Tabloid) patient drug information (Chemocare)
*Thioguanine (Tabloid) patient drug information (UpToDate)Thioguanine (Tabloid) patient drug information (UpToDate)
==History of changes in FDA indication==
* 1966-01-18: Initial approval
==History of changes in EMA indication==
*1966-01-18: EURD
==Also known as==
*Generic names: 6-TG, 6-thioguanine, 2-Amino-6-Mercaptopurine, tioguanine
*Brand name: Lanvis, Tabloid, Thioxlant
==References==
Category:Drugs
Category:Oral medications
Category:Antimetabolites
Category:Purine analogs
Category:Acute promyelocytic leukemia medications
Category:B-cell acute lymphoblastic leukemia medications
Category:Waldenström macroglobulinemia medications
Category:Acute myeloid leukemia medications (historic)
Category:FDA approved in 1966
Category:EMA approved in 1966
Category:WHO Essential Cancer Medicine
Thrombocytopenia and platelet dysfunction

*We have moved How I Treat articles to a dedicated page.
==Definition of thrombocytopenia==
Platelet count less than 150 x 109/L or less than the lower limit of normal as defined by a local laboratory.
==Evaluation==
May consist of:
*CBC with differential
*Comprehensive metabolic panel, including liver function tests (LFTs)
*Vitamin B12
*Folate
*Assessment for liver disease, hepatomegaly, fatty liver, splenomegaly
*Peripheral smear, platelet clumps
*Clinical history (bleeding, temporality, recent infections), TTP/aHUS
*Thrombotic history (e.g., heparin/HIT)
*Lifestyle factors (e.g. alcohol)
*Medications 
**MedlinePlus
**Aster & Bougie (2007) Drug-induced immune thrombocytopenia EuroPMC
*Hepatitis serologies
*HIV
*ANA, lupus
*Pseudothrombocytopenia, EDTA-induced clumping (draw sample in blue top citrate tube)
*Pregnancy/gestational thrombocytopenia
*ITP
==Relevant hematologic diagnoses==
*Atypical hemolytic uremic syndrome
*Glanzmann thrombasthenia
*Immune thrombocytopenia (ITP)
*Heparin-induced thrombocytopenia (HIT)
*Thrombocytopenia in liver disease
*Acquired thrombotic thrombocytopenic purpura
==Bleeding prevention==
===Tranexamic acid===
#TREATT: TREATT Trial Investigators. Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial. Lancet Haematol. 2025 Jan;12(1):e14-e22. Epub 2024 Dec 3. link to original article EuroPMC NCT03136445
Category:Hematology reference pages
Thrombocytopenia in liver disease - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main thrombocytopenia in liver disease page for regimens that include active treatment.
=Thrombocytopenia in liver disease with planned procedure=
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Alkhouri et al. 2020 (L-PLUS 1)	2013-10 to 2014-05 	Phase 3 (C)	Lusutrombopag	Higher requirement for platelet transfusion before the invasive procedure and rescue therapies for bleeding 7 days or fewer after the invasive procedure (primary endpoint)Endpoint: 91.1% vs 32%
Terrault et al. 2018 (ADAPT-2) 	2013-2017 	Phase 3 (C)	Avatrombopag 	Lower proportion of patients not requiring platelet transfusions or rescue procedures for bleeding up to 7 days after a scheduled procedure (primary endpoint)
Terrault et al. 2018 (ADAPT-1) 	2014-2017 	Phase 3 (C)	Avatrombopag 	Lower proportion of patients not requiring platelet transfusions or rescue procedures for bleeding up to 7 days after a scheduled procedure (primary endpoint)
Alkhouri et al. 2020 (L-PLUS 2)	2015-2017 	Phase 3 (C)	Lusutrombopag	Higher requirement for platelet transfusion before the invasive procedure and rescue therapies for bleeding 7 days or fewer after the invasive procedure (primary endpoint)
No active treatment.
===References===
# ADAPT-1: Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018 Sep;155(3):705-718. Epub 2018 May 17. link to original article EuroPMC NCT01972529
# ADAPT-2: Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018 Sep;155(3):705-718. Epub 2018 May 17. link to original article EuroPMC NCT01976104
# L-PLUS 1: Alkhouri N, Imawari M, Izumi N, Osaki Y, Ochiai T, Kano T, Bentley R, Trevisani F. Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020 Oct;18(11):2600-2608.e1. Epub 2020 Mar 20. link to original article EuroPMC JapicCTI-132323
# L-PLUS 2: Alkhouri N, Imawari M, Izumi N, Osaki Y, Ochiai T, Kano T, Bentley R, Trevisani F. Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020 Oct;18(11):2600-2608.e1. Epub 2020 Mar 20. link to original article EuroPMC NCT02389621
Category:Thrombocytopenia in liver disease regimens
Category:Disease-specific pages
Category:Cytopenias
Category:Null regimens
Thrombocytosis

==Definition==
Platelet count greater than or equal to 450 x 109/L (local reference ranges may vary).Elisa Rumi and Mario Cazzola. How I treat essential thrombocythemia. Blood 2016 128:2403-2414. EuroPMC
==Initial evaluation==
May consist of:
*CBC with differential
*Iron, total iron binding capacity (TIBC), ferritin
*JAK2 V617F mutation
*CALR exon 9 indels
*MPL exon 10 mutations
*Peripheral smear
*Splenectomy
*Clinical history (e.g. recent surgery or other reasons for reactive thrombocytosis), lifestyle factors
==References==
Category:Hematology reference pages
Thyroid cancer, BRAF-mutated

Back to Top
Note: these are regimens tested in biomarker-specific populations, please see the main thyroid cancer page for other regimens.
Last updated on 2024-07-23:2 regimens on this page
2 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Thyroid Carcinoma.
=Locally advanced or metastatic, all lines of therapy=
==Dabrafenib & Trametinib==
===Regimen===
FDA-recommended dose
Study 	Dates of enrollment	Evidence 	Efficacy
Subbiah et al. 2017 (ROAR)	2014-2016 	Phase 2, fewer than 20 pts in subgroup (RT)	ORR: 63% (95% CI, 35-85)
====Eligibility criteria====
*Biomarker: BRAF p.V600E
*Histology: Anaplastic thyroid cancer
====Targeted therapy====
*Dabrafenib (Tafinlar) 150 mg PO twice per day
*Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
===References===
# ROAR: Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13. Epub 2017 Oct 26. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT02034110
##Update: Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Ilankumaran P, Burgess P, Romero Salas T, Keam B. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022 Apr;33(4):406-415. Epub 2022 Jan 10. link to original article link to PMC article EuroPMC
==Vemurafenib monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence	Efficacy
Brose et al. 2016 (NO25530)	2011-2013 	Phase 2 	ORR: 38.5%, 95% CI 20.2-59.4
====Eligibility criteria====
*Biomarker: BRAF p.V600E
*Histology: Papillary thyroid cancer
*Prior treatment: Radioactive iodine
====Targeted therapy====
*Vemurafenib (Zelboraf) 960 mg PO twice per day
Continued indefinitely
===References===
# NO25530: Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1272-82. Epub 2016 Jul 23. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT01286753
Category:Biomarker-specific pages
Category:Thyroid cancer regimens
Category:Endocrine cancers
Category:Head and neck cancers
Thyroid cancer, medullary - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main MTC page for regimens that include active anticancer treatment.
=Locally advanced or metastatic disease, subsequent lines of therapy=
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Wells et al. 2011 (ZETA) 	2006-12 to 2007-11 	Phase 3 (C-RT)	Vandetanib 	Shorter PFSMedian PFS: 19.3 vs NYR mo(HR 2.17, 95% CI 1.45-3.23)
Elisei et al. 2013 (EXAM)	2008-2011 	Phase 3 (C-RT)	Cabozantinib	Shorter PFS
No active antineoplastic treatment. Included for reference purposes only.
===References===
# ZETA: Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. link to original article link to PMC article EuroPMC NCT00410761
# EXAM: Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864. link to original article link to PMC article EuroPMC NCT00704730
Category:Thyroid cancer regimens
Category:Histology-specific pages
Category:Endocrine cancers
Category:Head and neck cancers
Category:Null regimens
Ticagrelor (Brilinta)

==General information==
Class/mechanism: Reversible cyclopentyl-triazolo-pyrimidine class inhibitor of the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets, inhibiting platelet activation and aggregation.
Route: PO
Extravasation: n/a
==History of changes in FDA indication==
Note that this agent does not have a hematology-specific indication at this time.
*2011-07-20: Initial approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).
*2015-09-03: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
==Also known as==
*Brand names: Brilinta, Brilique, Ticalog
Category:Drugs
Category:Oral medications
Category:P2Y12 ADP inhibitors
Category:FDA approved in 2011
Ticlopidine (Ticlid)

==General information==
Class/mechanism: Irreversible thienopyridine class inhibitor of the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets, inhibiting platelet activation and aggregation.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Also known as==
*Brand names: Ticlid, Tilopin
Category:Drugs
Category:Oral medications
Category:P2Y12 ADP inhibitors
Category:FDA approved in 2001
Tigatuzumab (CS-1008)

==Mechanism of action==
Monoclonal antibody directed against the tumour necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2)
==Also known as==
*Code name: CS-1008
Category:Drugs
Category:Intravenous medications
Category:Anti-TRAIL-R2 antibodies
Category:Investigational drugs
Category:Stub
Tinzaparin (Innohep)

Withdrawn from US market in 2011
==General information==
Class/mechanism: Low molecular weight heparin, binds to antithrombin III, accelerating its activity and inhibiting factor Xa and thrombin.Tinzaparin (Innohep) package insert Tinzaparin (Innohep) package insert (locally hosted backup)Innohep manufacturer's website
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Patient drug information==
*Tinzaparin (Innohep) patient drug information (UpToDate)Tinzaparin (Innohep) patient drug information (UpToDate)
==History of changes in FDA indication==
*2000-07-14: Initial FDA approval: treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with Warfarin (Coumadin)
*2011-02-10: Voluntary recall as a voluntary measure after a dialogue with the FDA following an inspection at the production facility in Ballerup, Denmark. The dialogue concerned the production process and more specifically, the theoretical risk of presence of particulate matter in the released vials.
*2011: Withdrawn from US market. "LEO Pharma discontinued marketing all Innohep presentations after the recall due to low usage of the products in the US."
==Also known as==
*Brand name: Innohep, Tinprin
==References==
Category:Drugs
Category:Subcutaneous medications
Category:Anticoagulants
Category:Heparins
Category:Low molecular weight heparins
Category:Venous thromboembolism medications
Category:FDA approved in 2000
Category:Discontinued drugs
Tipifarnib (Zarnestra)

==Mechanism of action==
From the NCI Drug Dictionary: A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction. By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis.
==Also known as==
*Code name: R115777
*Brand name: Zarnestra
Category:Drugs
Category:Oral medications
Category:Farnesyltransferase inhibitors
Category:Investigational drugs
Tirabrutinib (Velexbru)

==Mechanism of action==
BTK inhibitor
==Diseases for which it is used==
*CNS lymphoma
*Waldenström macroglobulinemia
==History of changes in PMDA indication==
*2020-03-25: Newly indicated for the treatment of relapsed or refractory primary central nervous system (CNS) lymphoma.
*2020-08-21: New indications for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma.
==Also known as==
*Code name: GS-4059
*Brand name: Velexbru
Category:Drugs
Category:Oral medications
Category:BTK inhibitors
Category:CNS lymphoma medications
Category:Waldenström macroglobulinemia medications
Category:PMDA approved in 2020
Tirapazamine (Tirazone)

==Mechanism of action==
From the NCI Drug Dictionary: A benzotriazine di-N-oxide with potential antineoplastic activity. Tirapazamine is selectively activated by multiple reductases to form free radicals in hypoxic cells, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death. This agent also sensitizes hypoxic cells to ionizing radiation and inhibits the repair of radiation-induced DNA strand breaks via inhibition of topoisomerase II.
==Also known as==
*Code names: SR-4233, WIN-59075
*Brand name: Tirazone
Category:Drugs
Category:Intravenous medications
Category:Investigational drugs
Category:Stub
Tirofiban (Aggrastat)

==General information==
Class/mechanism: reversibly inhibits the glycoprotein IIb/IIIa receptor on platelets, preventing them from binding to fibrinogen, von Willebrand factor, and other adhesion molecules and thereby inhibiting platelet aggregation.
Route: IV
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Also known as==
*Brand name: Aggrastat
Category:Drugs
Category:Intravenous medications
Category:GPIIb-IIIa inhibitors
Category:FDA approved in 1998
Tisagenlecleucel (Kymriah)

==Mechanism of action==
From the NCI Drug Dictionary: Autologous T lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel direct the T lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells.
==Toxicity management==
*Link to REMS program
==Significant side effects==
==Diseases for which it is established==
*B-cell acute lymphoblastic leukemia
*Diffuse large B-cell lymphoma
*High-grade B-cell lymphoma
*Transformed lymphoma
==Diseases for which it is used==
*Follicular lymphoma
==Diseases for which it was used==
*Chronic lymphocytic leukemia
*Multiple myeloma
==History of changes in FDA indication==
*2017-08-30: Granted FDA regular approval for the treatment of patients up to age 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. (Based on ELIANA)
*2018-05-01: FDA approval expanded for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma. (Based on JULIET)
*2022-05-27: Granted accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. (Based on ELARA)
==History of changes in EMA indication==
*2017-08-30: Initial marketing authorisation
==History of changes in Health Canada indication==
*2018-09-05: Initial notice of compliance
*2022-12-19: Notice of compliance with conditions for adult patients with relapsed or refractory 1, 2, 3a follicular lymphoma (FL) after two or more lines of systemic therapy.
==Also known as==
*Code name: CART19, CTL-019
*Generic name: tisagenlecleucel-T, tisa-cel
*Brand name: Kymriah
Category:Anti-CD19 CAR T-cells
Category:Anti-CD3 cellular therapy
Category:Anti-CD19 cellular therapy
Category:Anti-CD137 cellular therapy
Category:Intravenous medications
Category:B-cell acute lymphoblastic leukemia medications
Category:Diffuse large B-cell lymphoma medications
Category:Follicular lymphoma medications
Category:High-grade B-cell lymphoma medications
Category:Transformed lymphoma medications
Category:Chronic lymphocytic leukemia medications (historic)
Category:Multiple myeloma medications (historic)
Category:REMS program
Category:FDA approved in 2017
Category:EMA approved in 2017
Category:Health Canada approved in 2018
Tisotumab vedotin (Tivdak)

==Mechanism of action==
From the NCI Drug Dictionary: An antibody-drug conjugate (ADC) comprised of a monoclonal antibody against human tissue factor (TF) covalently coupled, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antiangiogenic, anticoagulant and antineoplastic activities. Upon administration, tisotumab vedotin binds to cell surface TF and is internalized. The antibody moiety prevents binding of TF to factor VIIa (FVIIa) and interferes with the activation of factor X (FX) into FXa. This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. After internalization of the agent, the MMAE moiety is released by proteolytic cleavage. It then binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis.
==Diseases for which it is used==
*Cervical cancer
==History of changes in FDA indication==
*2021-09-20: Granted accelerated approval for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. (Based on innovaTV 204)
**2024-04-24: Granted regular approval for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. (Based on innovaTV 301)
==Also known as==
*Code name: HuMax-TF-ADC
*Generic name: tisotumab vedotin-tftv
*Brand name: Tivdak
Category:Drugs
Category:Intravenous medications
Category:Anti-TF antibody-drug conjugates
Category:Microtubule inhibitors
Category:Cervical cancer medications
Category:FDA approved in 2021